Q3 Revenue Drops 12.9% as Continuing-Ops Profit Falls to $568K
VASO has more than doubled off its 52-week low of $0.105 on elevated volume (1.8× avg).
Summary
Vaso reported Q3 2026 revenue of $10.8M, down 12.9% from $12.4M a year ago, with part of the decline tied to the healthcare IT divestiture. Continuing-operations net income fell to $568K from $1.6M, and adjusted EBITDA dropped to $691K from $1.3M on lower gross profit and higher income tax expense. Nine-month operating cash flow came in at $6.5M versus $9.0M, still positive but weaker. The balance sheet remains the story: cash and restricted cash stood at roughly $53.3M as of November 12, a large cushion relative to the company's small market value. The company has now fully exited network and IT services and is pitching improved efficiency in professional sales services and medical devices, but that improvement is anticipated, not yet reported.
At the time of this announcement, VASO was trading at $0.28 on OTC in the Technology sector, with a market capitalization of approximately $49.8M. The 52-week trading range was $0.11 to $0.34. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.